David P. Douglass Institution Verified

Sourced from institutional research profiles (UAMS TRI or ARA).

Associate Professor

University of Arkansas for Medical Sciences

faculty

Peds Pediatrics, College of Medicine

3 h-index 12 pubs 22 cited

Research Areas

Cancer Treatment and Pharmacology Cancer-related molecular mechanisms research Child and Adolescent Health Cancer Genomics and Diagnostics Pharmacological Effects and Toxicity Studies Birth, Development, and Health Cardiovascular Function and Risk Factors

Links

ORCID Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

David P. Douglass, an Associate Professor at the University of Arkansas for Medical Sciences, focuses his research on pediatric oncology, particularly the study of sarcomas and neuroblastomas. His recent publications investigate prognostic signatures for neuroblastoma, the role of pharmacotherapeutic agents in desmoid tumors, and the prioritization of novel agents for pediatric non-rhabdomyosarcoma soft tissue sarcomas. Douglass also contributes to understanding the clinical features and outcomes of young patients with low-grade non-rhabdomyosarcoma soft tissue sarcomas. His work extends to exploring therapeutic strategies for MYCN-amplified rhabdomyosarcoma and neuroblastoma, including targeting CDK9. Additionally, he has been involved in identifying novel genetic fusions in neonatal osteoblastic tumors and resolving variants of uncertain significance in Li-Fraumeni syndrome. Douglass also studies predictive risk factors for myocardial injury in children treated with anthracyclines.

Metrics

h-index: 3
Publications: 12
Citations: 22

Selected Publications

Correction: Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2026) DOI
Cancer-associated fibroblasts promote tumor progression in fusion-positive rhabdomyosarcoma (2025) DOI
Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2025) DOI
Clinical features and outcomes of young patients with low‐grade non‐rhabdomyosarcoma soft tissue sarcomas treated with a risk‐based strategy: A report from Children's Oncology Group study ARST0332 (2024) DOI
Development and validation of a 21-gene prognostic signature in neuroblastoma (2023) DOI
Abstract 1558: Targeting CDK9 via the small-molecule inhibitor enitociclib as a therapeutic strategy to treat <i>MYCN</i>-amplified rhabdomyosarcoma and neuroblastoma in children (2023) DOI
Neonatal osteoblastic tumor with a novel <i>PTBP1::FOSB</i> fusion (2023) DOI
The Role of Pharmacotherapeutic Agents in Children with Desmoid Tumors (2022) DOI
A Novel Germline TP53 Mutation in a Patient With Li-Fraumeni Syndrome: Resolving a Variant of Uncertain Significance (2021) DOI